Publication | Open Access

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

First-line PembrolizumabEsophageal CancerGastrointestinal OncologyMedicinePathologyHer2-positive OesophagealCancer TreatmentOncologyRadiation OncologyGastro-oesophageal Junction Cancer